AstraZeneca PLC shares fell over 6% following the failure of Wainua (eplontersen) in its Phase 3 ATTR-CM trial, which represents a significant lost revenue opportunity. Ionis Pharmaceuticals, which developed eplontersen and stands to earn royalties, saw its stock drop more than 20%. This setback creates an estimated $15 billion gap in AstraZeneca's $80 billion 2030 revenue target, though the company’s strong oncology pipeline offers some resilience. Despite this, the analyst maintains a Buy rating on AstraZeneca, expecting a potential 30% share price increase by 2030, while Ionis faces a sharper impact but retains long-term growth prospects due to its diversified pipeline.
The FTSE 100 fell due to AstraZeneca's 8% drop after a failed clinical trial for a heart disease drug, impacting its market value by £20 billion. Meanwhile, Computacenter surged over 13% following a strong trading update, and US semiconductor stocks ...
AstraZeneca's drug Wainua failed a key trial, causing its shares to fall 9%, the largest drop in the FTSE 100 that day. Jefferies notes the impact on the stock price exceeds the drug's actual valuation contribution, which is about 2% of net present v...
AstraZeneca and Ionis Pharmaceuticals saw their shares drop after their jointly developed heart disease drug, Wainua, failed a late-stage trial. The drug, designed as a monthly gene silencer injection, did not show a statistically significant benefit...
AstraZeneca's shares fell 9.55%, wiping £19 billion off its value, after its Wainua drug failed a major Phase III trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The trial did not meet its primary goal of reducing cardiovascular de...
AstraZeneca's shares fell nearly 9% after its experimental heart drug, Wainua, failed to meet the primary goal in a late-stage trial. The drug aimed to reduce deaths and heart-related emergencies over 140 weeks for patients with a rare heart conditio...
